SecBot SecBot
SECBOTREPLAY Home › Report › IOVA

IOVA · Q3 revenue ~$122M, +80% YoY

IOVANCE BIOTHERAPEUTICS, INC. · 8-K filed Nov 5, 2026 at 07:05 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 5, 2026 at 07:05 ET

Iovance Biotherapeutics reported record Q3 2026 revenue of ~$122M, up ~80% YoY, with gross margin improving to ~60%. The company maintained its FY26 revenue guidance of $410M-$420M and highlighted positive clinical data in NSCLC and sarcoma. Cash position of ~$382M is expected to fund operations well into 2029.

  • Q3 2026 total product revenue of ~$122M, up ~80% from ~$67M in Q3 2025 and ~22% from ~$99M in Q2 2026
  • U.S. Amtagvi revenue of ~$102M, up ~77% YoY and ~12% sequentially
  • Gross margin of ~60%, up from 56% in Q2 2026
  • R&D expenses decreased ~16% sequentially, marking fifth straight quarter of improvement

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access